Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Sponsor

Ou Bai, MD/PHD (Other)

Overall Status

Recruiting

CT.gov ID

NCT05821192

Collaborator

Second Hospital of Jilin University (Other), China-Japan Union Hospital, Jilin University (Other)

Enrollment

Location

Arm

21.3

Anticipated Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously shown promising efficacy.

Condition or Disease	Intervention/Treatment	Phase
Peripheral T-Cell Lymphoma, Not Otherwise Specified Angioimmunoblastic T-cell Lymphoma	Drug: Rituximab Drug: Gemcitabine Drug: Dexamethasone Drug: Cisplatin Drug: PD-1 monoclonal antibody	N/A

Detailed Description

Objective to evaluate the efficacy and safety of R-GDP (Rituximab, Gemcitabine, Dexamethasone, Cisplatin) plus PD-1 monoclonal antibody in patients with refractory or relapsed peripheral T cell lymphoma not otherwise specified or Angioimmunoblastic T-cell lymphoma.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

34 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.

Actual Study Start Date :

Mar 23, 2023

Anticipated Primary Completion Date :

Apr 18, 2023

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: R-GDP plus PD-1 monoclonal antibody Rituximab, Gemcitabine, Cisplatin, Dexamethasone, PD-1 monoclonal antibody	Drug: Rituximab 375mg/m2 by IV infusion once every 3 weeks Drug: Gemcitabine 1 g/m2 on Days 1 by IV infusion once every 3 weeks Drug: Dexamethasone 40 mg on Days 1 to 4 of each 3-week cycle by IV infusion Drug: Cisplatin 75 mg/m2 on Days 1 by IV infusion once every 3 weeks Drug: PD-1 monoclonal antibody 200mg on Days 2 by IV infusion once every 3 weeks

Arm

Intervention/Treatment

Experimental: R-GDP plus PD-1 monoclonal antibody

Rituximab, Gemcitabine, Cisplatin, Dexamethasone, PD-1 monoclonal antibody

Drug: Rituximab

375mg/m2 by IV infusion once every 3 weeks

Drug: Gemcitabine

1 g/m2 on Days 1 by IV infusion once every 3 weeks

Drug: Dexamethasone

40 mg on Days 1 to 4 of each 3-week cycle by IV infusion

Drug: Cisplatin

75 mg/m2 on Days 1 by IV infusion once every 3 weeks

Drug: PD-1 monoclonal antibody

200mg on Days 2 by IV infusion once every 3 weeks

Outcome Measures

Primary Outcome Measures

Objective response rate (ORR) [16 months]
Percentage of Complete remission (CR), and Partial remission (PR).

Secondary Outcome Measures

Progression-free survival (PFS) [24 months]
Progression-free survival#PFS# is defined as the time from the date of enrollment to the date of first documentation of progressive disease (PD) or death from any cause.
Overall survival (OS) [24 months]
Overall survival#OS# is defined as the time from the date of enrollment to the date of death from any cause.
Incidence of adverse events (AEs) [24 months]
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.
Serious Adverse Event (SAE) [24 months]
A serious adverse event will be considered any undesirable sign, symptom, or medical condition with one or more of the following outcomes: is fatal, is life-threatening requires or prolongs inpatient hospitalization results in persistent or significant disability/incapacity constitutes a congenital anomaly or birth defect

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with peripheral T cell lymphoma not otherwise specified or Angioimmunoblastic T-cell lymphoma confirmed by histopathology;
Age 18 to 70 years for all sexs;
Progressive disease or no response in patients who have received first-line chemotherapy (at least 2 cycles), and patients who refuse or can't suffer from intravenous chemotherapy;
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
Life expectancy ≥ 3 months;
There are measurable lesions (lymph nodes enlargement, nodal masses, enlargement of lymphoid organs and extranodal lesion that are measurable in two diameters (longest diameter and shortest diameter). A measurable node must have an longest diameter greater than 1.5 cm. A measurable extranodal lesion should have an longest diameter greater than 1.0 cm.);
Function of organs:
Hepatic function: Total bilirubin ≤ 1.5 times upper limit of normal (ULN), direct bilirubin ≤ 1.5 times ULN; aspartate aminotransferase (AST) or Alanine aminotransferase （ALT） ≤ 2.5 times ULN (5 times ULN if liver involvement with lymphoma);
Bone marrow function (without growth factor in 7 days before the first drugs): WBC ≥ 2.0×109/l; ANC ≥ 1.0×109/l; PLT ≥ 50×109/l; Hb ≥ 8g/dl;
Renal function: Creatinine ≤ 1.5 times ULN or creatinine clearance rate ≥ 30ml/min or creatinine clearance rate ≤ 2.5 times ULN;
Pulmonary function: blood oxygen saturation ≥ 95% in resting state without oxygen inhalation;
Coagulation function: international normalised ratio (INR) ≤ 1.5 times ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN (Patients whose prolonged PT or increased INR resulted in clotting factor inhibitors, should be selected at the investigator's discretion);
Heart function: LVEF ≥ 50%;

Exclusion Criteria:

Unrelieved toxic reaction CTCAE grade > 1 before the first drugs in this research (except adverse effects that won't affect this study, estimated by the investigator, such as alopecia);
There is an active infection, including but not limited to known active tuberculosis, known latent tuberculosis, herpes zoster and pneumonia;
Patient is known to be positive for Human immunodeficiency virus (HIV) infection; Or serological status reflect active hepatitis B virus(HBV) infection or active hepatitis

C virus (HCV) infection:

Patients with HBsAg(+), HBcAb (+) or HBsAg (+) should detect HBV-DNA. Patients who has HBV-DNA ≤ 1000IU/ml and agree to have anti-HBV therapy can be selected;
Patients with HCVAb (+) and HCV RNA < 15 IU/mL can be selected;
Heart failure with New York Heart Association （NYHA） grade III or IV, unstable angina pectoris, severe ventricular arrhythmias with poor control, acute myocardial ischemia showed by electrocardiogram or had myocardial infarction in 6 months before screening. Or patients can't suffer from chemotherapy due to other heart function disorders, estimated by investigator;
Intractable nausea or vomiting that can't be controlled by supportive care, chronic gastrointestinal diseases or dysphagia of capsules, or had intestinal resection which may affect the drug absorption;
The investigator determined or other evidence showed patients have severe or poorly controlled systemic diseases, including poorly controlled hypertension and active bleeding body constitution. Patients with thrombotic diseases such as pulmonary embolism and deep venous thrombosis are also not suitable to participate in this study;
Patients have interstitial pneumonia or once had chemotherapy-induced interstitial pneumonia during chemotherapy, who have treatment risk in the estimation of investigator;
Pregnant or lactating women;
The investigator determine the patients having other infectors which may affect compliance;